Coherus BioSciences, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Coherus BioSciences, Inc. on June 3, 2016, covering events occurring on May 31, 2016. The filing relates to the exercise of an over-allotment option in connection with a public offering of common stock that initially closed on May 26, 2016.
Key Financial Metrics
- Offering Proceeds: The Company expects net proceeds of approximately $69.1 million from the total offering (initial shares plus additional shares), after underwriting discounts, commissions, and estimated offering expenses.
- Share Issuance: The total offering includes 3,500,000 shares sold at the initial closing and 525,000 Additional Shares purchased under the over-allotment option.
- Offering Price: $18.00 per share (before underwriting discount).
- Other Metrics: The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity positions.
Material Changes
The primary material event reported is the exercise of the over-allotment option by the underwriter, Barclays Capital Inc., to purchase 525,000 additional shares. This action increases the total capital raised from the offering compared to the initial closing on May 26, 2016.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on future operations, or specific risk factors beyond the standard disclosure of the offering mechanics. The document focuses solely on the completion of the capital raise.
Key Facts for Investor Verification
- Verify the final net proceeds of $69.1 million against the actual cash received after all expenses.
- Confirm the total number of shares outstanding post-offering (initial 3,500,000 plus 525,000 additional shares).
- Review the use of proceeds disclosed in the related prospectus to understand capital allocation plans.
- Check subsequent filings for any updates on the Company's cash position or operational milestones funded by this capital.